These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2952268)

  • 21. D-1 dopamine receptors and arousal.
    Ongini E
    Adv Exp Med Biol; 1988; 235():169-78. PubMed ID: 2976250
    [No Abstract]   [Full Text] [Related]  

  • 22. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
    O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
    Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine-dependent behavioural stimulation by non-peptide delta opioids BW 373U86 and SNC 80: 3. Facilitation of D1 and D2 responses in unilaterally 6-hydroxydopamine-lesioned rats.
    Pinna A; Di Chiara G
    Behav Pharmacol; 1998 Feb; 9(1):15-21. PubMed ID: 9832944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural analogs of SCH 23390 as discriminators of dopamine receptor subtypes: behavioral interactions between D-1 and D-2 agonists and antagonists.
    O'Boyle KM; Molloy AG; Mashurano M; Waddington JL
    Psychopharmacol Bull; 1986; 22(3):599-604. PubMed ID: 2879303
    [No Abstract]   [Full Text] [Related]  

  • 25. Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation.
    Pifl C; Hornykiewicz O
    Eur J Pharmacol; 1988 Jan; 146(1):189-91. PubMed ID: 3258244
    [No Abstract]   [Full Text] [Related]  

  • 26. Selective dopamine D2 receptor reduction enhances a D1-mediated oral dyskinesia in rats.
    Rosengarten H; Schweitzer JW; Friedhoff AJ
    Life Sci; 1986 Jul; 39(1):29-35. PubMed ID: 3523096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D1 antagonists potentiate the durations of bar and cling catalepsy and the dorsal immobility response in rats.
    Meyer ME; Cottrell GA; Van Hartesveldt C
    Pharmacol Biochem Behav; 1992 Mar; 41(3):507-10. PubMed ID: 1533938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New putative selective agonists at the D-1 dopamine receptor: behavioural and neurochemical comparison of CY 208-243 with SK&F 101384 and SK&F 103243.
    Murray AM; Waddington JL
    Pharmacol Biochem Behav; 1990 Jan; 35(1):105-10. PubMed ID: 1969161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of [3H]nicotine binding in hypothalamic and cortical membranes by dopamine D1 receptors.
    Fuxe K; von Euler G; Finnman UB; Agnati LF
    Acta Physiol Scand; 1989 Jun; 136(2):295-6. PubMed ID: 2528887
    [No Abstract]   [Full Text] [Related]  

  • 30. Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease.
    Breese GR; Mueller RA; Napier TC; Duncan GE
    Adv Exp Med Biol; 1986; 204():197-215. PubMed ID: 2947429
    [No Abstract]   [Full Text] [Related]  

  • 31. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine.
    Miller R; Beninger RJ
    Prog Neurobiol; 1991; 36(3):229-56. PubMed ID: 1673254
    [No Abstract]   [Full Text] [Related]  

  • 32. Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.
    Pettersson I; Liljefors T; Bøgesø K
    J Med Chem; 1990 Aug; 33(8):2197-204. PubMed ID: 1973733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions.
    Mailman RB; Schulz DW; Lewis MH; Staples L; Rollema H; Dehaven DL
    Eur J Pharmacol; 1984 May; 101(1-2):159-60. PubMed ID: 6235121
    [No Abstract]   [Full Text] [Related]  

  • 34. D1/D2 dopamine receptor interaction at the biochemical level.
    Strange PG
    Trends Pharmacol Sci; 1991 Feb; 12(2):48-9. PubMed ID: 1850879
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of dopamine D1 antagonists SCH23390 and SK&F83566 on locomotor activities in rats.
    Meyer ME; Cottrell GA; Van Hartesveldt C; Potter TJ
    Pharmacol Biochem Behav; 1993 Feb; 44(2):429-32. PubMed ID: 8446676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D1 receptors mediated vacuous chewing in the rat: a model of tardive dyskinesia.
    Diana M; Collu M
    Pharmacol Res; 1990; 22 Suppl 3():45. PubMed ID: 2097639
    [No Abstract]   [Full Text] [Related]  

  • 38. Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.
    Mashurano M; Waddington JL
    Neuropharmacology; 1986 Aug; 25(8):947-9. PubMed ID: 3490631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible involvement of differing classes of dopamine D-2 receptors in yawning and stereotypy in rats.
    Yamada K; Nagashima M; Kimura H; Matsumoto S; Furukawa T
    Psychopharmacology (Berl); 1990; 100(2):141-4. PubMed ID: 1968276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.